New Whitepaper: Origination in the Age of AI–How signal-driven infrastructure is replacing broker-dependent deal flow.Read now↗

PE Firms M&A Firms Commercial Lenders Investment Banks
Deal Origination
End-to-end outreach infrastructure that sources proprietary deal flow.
Data & Research
TAM mapping, data enrichment, custom scraping, and automated research.
Trigger Intelligence (Signals)
Signal-driven deal intelligence delivered to your CRM, Slack, and email.
Resources
Playbooks
Channel-specific outreach playbooks for deal origination.
All research
Comparison posts, methodology, and analysis from the Tentt team.
Reports
Monthly market reports on M&A and private equity activity.
Tools
Free calculators for M&A, lending, and deal analysis.
Whitepaper↗
Origination in the Age of AI.
About
Book an intro call

Teva — Acquisitions & M&A Deals

3 deals

Tracking 3 M&A deals by Teva.

Teva acquires Emalex Biosciences for up to $900m - Globes - Israel Business News

HealthcareMerger

Teva→Emalex Biosciences

Apr 29, 2026

Teva (TEVA) Announces Acquisition of Emalex Biosciences - GuruFocus

HealthcareNew JerseyMerger

Teva→Emalex Biosciences

Apr 29, 2026

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) — SEC 8-K Filing

HealthcareAdd-on

Teva→Emalex Biosciences

Apr 29, 2026